注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Alpine Immune Sciences Inc是一家生物製藥公司。該公司致力於發現和開發基於蛋白質的免疫療法,以治療癌症、自身免疫和炎症性疾病。該公司的科學平台使用定向進化過程將免疫球蛋白超家族(IgSF)的天然免疫系統蛋白轉化為能夠調節人類免疫系統的多靶點療法。其候選產品包括ALPN-101、ALPN-202和ALPN-303。ALPN-101是一種雙重誘導型T細胞共刺激劑(ICOS)和分化簇28(CD28)拮抗劑,旨在治療自身免疫性疾病和炎症性疾病。其腫瘤學項目是ALPN-202,一種用於治療癌症的條件性CD28共刺激劑和雙重檢查點抑製劑。ALPN-303是一種雙重B細胞細胞因子拮抗劑,用於治療B細胞介導的疾病。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Peter A. Thompson | 61 | 2016 | Independent Director |
Andrew M. Scharenberg | - | - | Scientific Advisory Board Chairman |
Robert E. Conway | 67 | 2017 | Independent Director |
Mitchell H. Gold | 53 | 2015 | Executive Chairman & CEO |
James N. Topper | 59 | 2016 | Independent Director |
Paul Tumeh | - | - | Member of Scientific Advisory Board |
Manish J. Butte | - | - | Member of Scientific Advisory Board |
Xiangmin Cui | 55 | 2019 | Independent Director |
John A. Thompson | - | 2018 | Member of Scientific Advisory Board |
Anne Davidson | - | - | Member of Scientific Advisory Board |
Vijay Kumar Kuchroo | 68 | 2019 | Member of Scientific Advisory Board |
James Welsh | - | 2018 | Member of Scientific Advisory Board |
Rafi Ahmed | - | 2018 | Member of Scientific Advisory Board |
Natasha A. Hernday | 51 | 2020 | Independent Director |
Jorn Drappa | 58 | 2022 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核